Pancreatic Cancer Research

ResearcherLanzhou University Second HospitalActive in the last 2 years

Wence Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0529-7777; OpenAlex author ID A5075290229, A5088457970. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 29)
Trials
0
Grants
0
Labs led
2
Collaborators
35
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: 10 papers · 2023: 8 papers · 2024: 7 papers · 2025: none · 2026: 3 papers

Papers 32

  1. Cordycepin inhibits pancreatic cancer progression and enhances gemcitabine sensitivity by targeting the CDK2/E2F2 axis to modulate TNNI2 expression. Last author DOI 10.1016/j.bcp.2026.118299↗
  2. SLPI/FBW7/c-Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity. Last author DOI 10.1111/cas.70369↗
  3. Post-Translational Modifications in Pancreatic Cancer: Mechanisms to Clinical Applications. Last author DOI 10.1111/jgh.70441↗
  4. Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma cell line. Co-author DOI 10.1007/s13577-024-01100-y↗
  5. KRT19 is regulated by miR-642a-5p and promotes pancreatic cancer progression through the Wnt/β-catenin pathway. Last author DOI 10.1016/j.isci.2024.110782↗
  6. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-024-56464-w↗
  7. Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1. Last author DOI 10.1186/s12885-024-12588-w↗
  8. Global burden of pancreatic cancer attributable to metabolic risks from 1990 to 2019, with projections of mortality to 2030. Last author DOI 10.1186/s12889-024-17875-6↗
  9. Long non-coding RNA MIR4435-2HG promotes pancreatic cancer progression by regulating ABHD17C through sponging miR-128-3p. Last author DOI 10.21037/tcr-24-51↗
  10. Integrated analysis of scRNA-seq and bulk RNA-seq reveals that GPRC5A is an important prognostic gene in pancreatic cancer and is associated with B-cell Infilt… Last author DOI 10.3389/fonc.2024.1283164↗
  11. Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis. Co-author DOI 10.1080/21645515.2023.2269794↗
  12. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer. Last author DOI 10.1155/2023/3419401↗
  13. Time trend of pancreatic cancer mortality in the Western Pacific Region: age-period-cohort analysis from 1990 to 2019 and forecasting for 2044. Last author DOI 10.1186/s12885-023-11369-1↗
  14. Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer. Last author DOI 10.32604/or.2023.026959↗
  15. Comprehensive Analysis Identifies PKP3 Overexpression in Pancreatic Cancer Related to Unfavorable Prognosis. Last author DOI 10.3390/biomedicines11092472↗
  16. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Reveals That TAM2-Driven Genes Affect Immunotherapeutic Response and Prognosis in Pancreatic … Last author DOI 10.3390/ijms241612787↗
  17. Nomograms for Predicting the Risk and Prognosis of Liver Metastases in Pancreatic Cancer: A Population-Based Analysis. Last author DOI 10.3390/jpm13030409↗
  18. Immunocyte Infiltration Analysis and Immunohistochemistry Identify EVL as a Potential Prognostic Biomarker for Pancreatic Cancer. Last author DOI 10.3390/jpm13030433↗
  19. Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer. Last author DOI 10.1002/jcla.24381↗
  20. The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate. Last author DOI 10.1016/j.bbcan.2022.188826↗
  21. The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1080/17474124.2022.2088506↗
  22. Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer. Last author DOI 10.1155/2022/4661929↗
  23. Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression. Last author DOI 10.3389/fimmu.2022.1038650↗
  24. Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations. Last author DOI 10.3389/fimmu.2022.844401↗
  25. Neutrophils in pancreatic cancer: Potential therapeutic targets. Last author DOI 10.3389/fonc.2022.1025805↗
  26. Challenges and Opportunities Associated With Platelets in Pancreatic Cancer. Last author DOI 10.3389/fonc.2022.850485↗
  27. Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis. Co-author DOI 10.3389/fphar.2022.979215↗
  28. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Last author DOI 10.3390/biom12101450↗
  29. The Application of Exosomal MicroRNAs in the Treatment of Pancreatic Cancer and Its Research Progress. Last author DOI 10.1097/mpa.0000000000001713↗
  30. LncRNA SNHG16 contributes to tumor progression via the miR-302b-3p/SLC2A4 axis in pancreatic adenocarcinoma. Last author DOI 10.1186/s12935-020-01715-9↗
  31. Current understanding of ferroptosis in the progression and treatment of pancreatic cancer. Last author DOI 10.1186/s12935-021-02166-6↗
  32. LncRNA SNHG16 Contributes to Tumor Progression via miR-302b-3p/SLC2A4 in Pancreatic Cancer Last author DOI 10.21203/rs.3.rs-64744/v1↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenkai Jiang · 11 shared papers, 2022–2024 · strength 2.42
  2. Shi Dong · 9 shared papers, 2021–2024 · strength 1.77
  3. Zhou Chen · 8 shared papers, 2021–2024 · strength 1.68
  4. Yan Du · 7 shared papers, 2022–2023 · strength 1.53
  5. Huaqing Shi · 6 shared papers, 2022–2024 · strength 1.24
  6. Ru He · 5 shared papers, 2022–2024 · strength 1.05
  7. Wenkai Jiang · 4 shared papers, 2021–2026 · strength 1.02
  8. Xin Li · 5 shared papers, 2021–2023 · strength 0.94
  9. Weixiong Zhu · 3 shared papers, 2022–2026 · strength 0.89
  10. Changpeng Chai · 4 shared papers, 2022–2024 · strength 0.75
  11. Hao Xu · 4 shared papers, 2021–2024 · strength 0.71
  12. Guoqing Zhang · 2 shared papers, 2026 · strength 0.70
  13. Ru He · 2 shared papers, 2024–2026 · strength 0.69
  14. Huan Tang · 3 shared papers, 2024 · strength 0.55
  15. Cheng Yu · 3 shared papers, 2024 · strength 0.55
  16. Hao Ming Xu · 3 shared papers, 2020–2022 · strength 0.54
  17. Bo Zhang · 3 shared papers, 2020–2024 · strength 0.47
  18. Xin Li · 2 shared papers, 2023 · strength 0.42
  19. Fangfang Han · 2 shared papers, 2022–2024 · strength 0.38
  20. Xin Li · 2 shared papers, 2021 · strength 0.35
  21. Zhengfeng Wang · 2 shared papers, 2022–2024 · strength 0.33
  22. Haofei Chen · 1 shared paper, 2026 · strength 0.32
  23. Xiao Li · 1 shared paper, 2024 · strength 0.28
  24. Wenlong Zhang · 1 shared paper, 2022 · strength 0.22
  25. Jubao Niu · 1 shared paper, 2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.